Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases
Aldena Therapeutics, a private biotech company pioneering siRNA- based therapies for dermatological indications, has chosen PCI Pharma Services (PCI) , a world-leading global contract development and manufacturing organization (CDMO) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions, all under one roof at PCI’s San Diego facility.
- Aldena Therapeutics, a private biotech company pioneering siRNA- based therapies for dermatological indications, has chosen PCI Pharma Services (PCI) , a world-leading global contract development and manufacturing organization (CDMO) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions, all under one roof at PCI’s San Diego facility.
- Dermatological diseases affect more than 900 million people worldwide.
- Significant advancements in the treatment of various skin conditions and disorders have been made.
- With the siRNA-based approach, Aldena develops advanced and long-lasting treatments for skin conditions.